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Successful treatment of chronic myelogenous leukemia is based on inhibitors binding to the ATP site of the deregulated breakpoint cluster region (Bcr)-Abelson tyrosine kinase (Abl) fusion protein.
Recently, a new type of allosteric inhibitors targeting the Abl myristoyl pocket was shown in preclinical studies to overcome ATP-site inhibitor resistance arising in some patients. Using NMR and smallangle X-ray scattering, we have analyzed the solution conformations of apo Abelson tyrosine kinase (c-Abl) and c-Abl complexes with ATPsite and allosteric inhibitors. Binding of the ATP-site inhibitor imatinib leads to an unexpected open conformation of the multidomain SH3-SH2-kinase c-Abl core, whose relevance is confirmed by cellular assays on Bcr-Abl. The combination of imatinib with the allosteric inhibitor GNF-5 restores the closed, inactivated state. Our data provide detailed insights on the poorly understood combined effect of the two inhibitor types, which is able to overcome drug resistance.
CML | heteronuclear NMR | protein dynamics P rotein kinases, such as Abelson tyrosine kinase (c-Abl), control numerous cellular signal pathways, and therefore require tight regulation (1) . Modulation of c-Abl activity is achieved by an autoinhibitory mechanism involving the N-terminal region of the protein (1, 2) . A myristoyl moiety covalently bound to Gly2 occupies a deep pocket located in the C-lobe of the kinase domain and stabilizes docking of the SH3 and SH2 domains to the kinase domain (3) (4) (5) (Fig. 1 ). In the oncogenic fusion protein BcrAbl, this crucial autoinhibition is lost as a result of chromosomal translocation, leading ultimately to chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (6, 7) .
The ATP-binding site inhibitors imatinib (STI-571/Gleevec), nilotinib (AMN-107/Tasigna), and dasatinib (Sprycel) constitute the front-line therapy against CML (8) (9) (10) (11) . However, spontaneous point mutations render these inhibitors ineffective and cause clinical relapse in advanced-phase patients (12, 13) . Although nilotinib and dasatinib retain their efficacy against many of the imatinib-resistant mutants, the "gatekeeper" T334I mutation (T315I in Abl 1a numbering) abrogates the binding of all three inhibitors (12) . Emergence of this multidrug-resistant mutant, which occurs in ∼15% of patients with resistance to imatinib, has stimulated the search for new therapeutics (14) . Recently, several new ATP-competitive inhibitors that are active against the T334I mutant (15-17) have been developed, and one of these, ponatinib (Iclusig) (15) , has received US Food and Drug Administration approval. An alternative approach has resulted from the discovery of allosteric inhibitors, which bind to the myristoyl-binding pocket of c-Abl (18, 19) . Subsequent studies have revealed that combining allosteric inhibitors with ATP-competitive inhibitors overcomes T334I-related resistance in an in vivo model and may be a relevant therapeutic strategy (20) . The importance of the myristoyl-binding pocket is further supported by the discovery of small-molecule c-Abl activators that bind to this site (21, 22) .
c-Abl and other tyrosine kinases are regulated by complicated allosteric interactions between their constituent domains (5) . Whereas crystallographic structures have laid the foundation for our current understanding of c-Abl regulation, the vast majority of solved structures represent the isolated kinase domain in complex with small molecules. Only two reports by Kuriyan and coworkers (3, 5) provide structures of the entire minimal autoregulatory fragment of c-Abl, which comprises the SH3, SH2, and kinase (also termed SH1) domains. In both cases, the protein was complexed with an ATP-site inhibitor and a myristoyl chain attached covalently to Gly2 or added in trans. Three structural features were identified as requirements for the assembly of a "closed," inactive state (5) (Fig. 1A ): (i) docking of the SH3 domain to a polyproline helix in the SH2-kinase linker, (ii) docking of the SH2 domain to the kinase domain facilitated by the binding of the myristoyl moiety, and (iii) the clamp formed by the N-terminal cap region. The removal of these "linchpins" resulted in an "activated" c-Abl mutant with the SH3-SH2-kinase domains arranged into an elongated structure with a direct contact between the SH2 domain and the N-lobe of the kinase (5). This has inspired further studies on the role of the SH2 domain in the regulation of c-Abl and other kinases (23) (24) (25) .
Crystal structures represent frozen snapshots of protein states that may not reflect all physiologically relevant conformations. In particular, it is expected that the active forms of c-Abl and other kinases undergo dynamic exchange, which makes them difficult to crystallize. Indeed, for example, the apo form of c-Abl has resisted crystallization so far. In principle, solution NMR can provide much of the missing dynamic information to understand protein function (26) . However, its applicability to larger systems is restricted by its inherent size limit, its low sensitivity, and the need for isotope labeling. Thus, so far, solution conformations Significance Current understanding of the interactions of Abelson tyrosine kinase (c-Abl) and other kinases with inhibitors is largely based on crystallographic structures. These present frozen snapshots of molecules and may not always reflect physiologically relevant conformations and dynamics. Our solution NMR study of various c-Abl complexes with allosteric and ATP-competitive inhibitors reveals a dynamic equilibrium between several c-Abl conformations that is distinctly modulated by both types of inhibitors. The observation of a hitherto unknown open state of the c-Abl•imatinib complex can explain an unusual doseresponse in cellular inhibition assays. Our data provide detailed insight into the combined effect of the two inhibitor types, which is able to overcome drug resistance. This may have important implications for the development of new drugs.
and dynamics have been analyzed by NMR for smaller fragments of protein kinases comprising the catalytic and/or adjacent domains, for example, of protein kinase A (27, 28) , MAP kinase p38 (29, 30) , and Eph receptor tyrosine kinase (31) , as well as c-Abl (32) (c-Abl ; throughout this report the amino acid numbering follows the 1b isoform). Here, we have determined the solution conformation and domain motions of the considerably larger autoregulatory fragment c-Abl 83-534 (designated as c-Abl in the following when clear from the context), which comprises the SH3, SH2, and kinase domains (Fig. 1B) , by advanced NMR experiments in combination with small-angle X-ray scattering (SAXS). The data provide the first structural information on the apo form of c-Abl in the absence of inhibitors, which is shown to adopt the "closed" conformation. Unexpectedly, the addition of the catalytic site inhibitor imatinib induces a large structural rearrangement characterized by the detachment of the SH3-SH2 domains from the kinase domain and the formation of a dynamic "open" inactive state, which is inhibited in the ATP site. As a consequence of this opening, Tyr245 within the SH2-kinase linker becomes exposed. The in vivo relevance of this unexpected opening is corroborated by an observed increase in Tyr245 phosphorylation at moderate imatinib concentrations in cellular assays on full-length Bcr-Abl. In contrast to imatinib, addition of the myristoyl pocket inhibitor GNF-5 (20) to apo c-Abl induces only local changes around the myristoyl-binding pocket and keeps the protein in the "closed" state. However, addition of GNF-5 to the "open" c-Abl•imatinib complex restores the "closed," inactive conformation. These findings on the allosteric actions of ATP and myristoyl pocket inhibitors reveal molecular details of their recently reported synergy to overcome drug resistance and may help to devise new strategies for drug development. (Fig. S1A) , c-Abl•imatinib showed significant chemical shift changes over the entire protein sequence, encompassing not only the kinase domain but the SH3 and SH2 domains ( Fig. 2B and Fig. S2B ), which suggests large structural rearrangements of all domains upon binding of imatinib. The spectra of c-Abl•imatinib also have increased signal-to-noise ratios relative to the apo form at the same protein concentration (Fig. S1A ). This is caused by increased nanosecond flexibility and concomitant line narrowing of the c-Abl•imatinib complex, as well as by micro-to millisecond conformational exchange and concomitant line broadening of the apo form. The latter coincides with very low stability of the apo protein preparations, which largely increased upon addition of imatinib (Fig. S3) .
In contrast to c-Abl•imatinib, the 1 H-15 N TROSY spectrum of the complex with the allosteric inhibitor GNF-5 closely resembled that of the apo form ( Fig. 2B and Fig. S1B ). Strikingly, the vast majority of the kinase N-lobe resonances were found missing, and only 12 assignments were obtained for this domain of the protein (Tables S1 and S2 ). Apparently, both in the apo form and in the c-Abl•GNF-5 complex, the N-lobe undergoes conformational exchange on the micro-to millisecond time scale, whereas the other domains are more stable. The chemical shift perturbations induced by GNF-5 relative to the apo form are mostly limited to the immediate vicinity of the myristoylbinding pocket in the kinase C-lobe, whereas the SH3 and SH2 domains remain largely unaffected ( Fig. 2B and Fig. S2B ). Notably, despite the high similarity of the spectra of the apo and GNF-5-bound forms, a significant increase in sample stability was also observed upon the binding of this allosteric inhibitor (Fig. S3) .
Motivated by the recent finding that a combination of ATP and myristoyl pocket inhibitors has the potential to overcome drug resistance of the gatekeeper mutant (20) , we investigated a ternary complex of c-Abl with both imatinib and GNF-5. The (Tables S1 and S2) , consistent with the notion that the conformational exchange of the N-lobe in the apo and GNF-5-bound forms is largely suppressed by the binding of imatinib. Relative to the apo form, pronounced chemical shift changes are observed for the ternary complex in the vicinity of the ATP-and myristoyl-binding pockets (Fig. 2B) . However, within the SH3 and SH2 domains, the chemical shifts are much closer to the apo and GNF-5-bound forms than to the imatinib complex (Fig. S2 ). This indicates that the imatinibinduced conformational change in the SH3 and SH2 domains is largely reversed by the action of GNF-5. (33) . A small number of RDCs (five or more per domain) suffices to determine the orientation tensor, provided that the directions of the measured bond vectors are isotropically distributed (34) . We have used this information from RDCs to determine the relative orientation of the individual domains of c-Abl in its different states. Fig. S4 shows the measured 1 D NH RDCs for all three c-Abl•inhibitor complexes (apo c-Abl was not stable enough for the required measurement period of several days) against values predicted from the atomic coordinates of the c-Abl crystal structure in its closed form (3) but fitting the orientation tensors separately for the SH3, SH2, kinase N-lobe, and kinase C-lobe domains. Parameters for all obtained orientation tensors are listed in Table S3 . The back-calculated and observed dipolar couplings are in excellent agreement for all complexes, considering the 2-to 5-Hz precision of the RDC measurement and the 1.8-Å resolution of the X-ray structure.
The correlation coefficient between individual orientation tensors (Table 1) is a measure of their collinearity (35) and indicates whether two domains have relative orientations similar to the coordinates used for their fit. For the ternary imatinib/ GNF-5 complex, the orientation tensors of all domains are highly correlated, indicating that all domains are docked in a very similar orientation as in the crystal structure. In contrast, the orientation tensors of the c-Abl•GNF-5 complex show only high correlations between the SH3, SH2, and kinase C-lobe domains, whereas the correlation coefficients from these domains to the N-lobe are significantly reduced. Therefore, the N-lobe clearly has either reoriented as a single conformation or is undergoing exchange between different conformations, which both would lead to a lower correlation coefficient. Conformational exchange on the micro-to millisecond time scale is the most likely explanation, because it is confirmed by the line broadening in this domain.
The situation is again strongly different for the c-Abl•imatinib complex. Here, many RDCs can be detected in all domains, including the kinase N-lobe (Fig. S4) , and the kinase N-and C-lobes correlate highly in their tensors, and hence in their orientation (Table 1) . However, all correlation coefficients from the N-or C-lobe to the SH2 or SH3 domain are strongly reduced, which indicates that the SH2 and SH3 domains have changed their orientation relative to the kinase and possibly also have become flexible. Furthermore, the correlation coefficient between the SH2 and SH3 domains is slightly reduced. Additional insight is obtained from the amplitudes of the orientation tensors (Table S3) : Although the amplitudes for the SH2, kinase N-lobe, and kinase C-lobe domains are comparable, the amplitude for the SH3 domain is almost twice smaller, which clearly proves the dynamical averaging of the SH3 orientation relative to the other domains. Although the considerable size of the c-Abl complexes limited the sensitivity of 15 N relaxation experiments, information on the time scale of the domain motions in the different complexes could be obtained from 15 N longitudinal (R 1 ) and transverse (R 2 ) relaxation rates (Fig. 3A) . Using average values for the individual domains, the ratios of R 1 and R 2 correspond to rotational correlation times, τ c , between 27 and 31 ns for all domains in the GNF-5 and ternary imatinib/GNF-5 complexes, excluding large interdomain motions on the nanosecond time scale (Fig. 3A and Table S4 ). Such uniform rotational L317  V275  W129  L490  A384  V170  R502   L395  V289   I462  N113  H114  L203   L228  L285   L107  T102 C324  V467  C119  K473  V279  I312  I101  T334  F211   S436  L232  T123  V86  Q122  Y112  K434  E428   N498  V130  A307  D400  T136  Y339   E335  H221   S284   T425   G391  E348  H265  G104  Y459   I379  S181   Y272   Y204  K438   L169   N133   T197  N125  R381  N377  G278   D474  S465  Y89   I135  G128   Y432 T230   V323  S504   T98   S500  G126  G201  G116   G273  T231   G340  G227  G111   T213   G270   G455   A121   E311   C349  K310   L343  F168   E187   Y186   R185   R194   I229   W280   L320   I332   Q496   E327   E353   T262   Y276  L321   K376   F435   M263   Y331   R347   S404   V487   Y488   W497   N387   L217   A399   A155   V151   L214   V224 M456   E216   S222  E157  Q352  K124   S206   A215   S94   C388   R492   T296   G402   G201a  G166   G322   G188   R386   L160   T223   N212   M477   K290   A  B   W146   T136   V130   SH3   SH2 kin-N kin-C correlation times are consistent with a fully assembled closed state observed in the c-Abl crystal structure (Fig. 1A) . In contrast, the rotational correlation times of the imatinib complex decrease from the kinase (30-31 ns) over the SH2 domain (25 ns) to the SH3 domain (21 ns), demonstrating that the SH2 and SH3 domains move relative to the kinase within nanoseconds.
Both RDC and 15 N relaxation data indicate that the imatinib complex adopts a dynamic open-inhibited conformation with a disrupted SH3-SH2/kinase domain interface such that the SH3 domain becomes detached from the rest of the molecule. To corroborate this finding, we carried out solution SAXS experiments, which should be highly sensitive to the expected considerable changes in the overall shape of the protein. It is obvious from the raw data (Fig. 3B ) that the overall shape of the molecules in the apo state and in the GNF-5 and ternary imatinib/ GNF-5 complexes must be similar, whereas the imatinib complex differs. Indeed, for apo c-Abl, as well as the GNF-5 and ternary imatinib/GNF-5 complexes, the radii of gyration, R gyr , (27 Å) and the maximal dimensions of the scattering particle, D max , (85-88 Å) calculated from the scattering profiles are almost identical (Fig. 3C) . Moreover, they closely match literature values for the assembled, closed state of c-Abl (R gyr = 28 Å, D max = 80 Å) (3). This finding indicates that the GNF-5 and ternary imatinib/GNF-5 complexes are in the assembled form. In addition, the highly similar SAXS data and Structural Models of c-Abl Complexes. To gain insight into the molecular structure of c-Abl•inhibitor complexes, we have carried out rigid-body refinement structure calculations with the program Xplor-NIH (36), using the highly complementary RDC and SAXS data (Tables S5 and S6 ) as constraints for repositioning of the individual domains (37, 38) . For each complex, 200 structural models were generated and a best set of 20 was selected.
For the ternary c-Abl•imatinib/GNF-5 complex, the calculated structures (Fig. 4A) adopt the same overall domain arrangement as the fully assembled c-Abl X-ray structure (Fig. 4D ) and the best 20 agree, on average, within 3.2 Å to its coordinates (Table  S7) . Fig. 4B depicts the best-scored models for c-Abl•GNF-5. In agreement with the SAXS and NMR data, the calculated structures of this complex are in a closed state, although the relative position of the kinase N-lobe with respect to the C-lobe varies and deviates by up to ∼10 Å from the crystal structure in the best-scored models. The lower definition of the kinase N-lobe is in agreement with the conformational exchange in this domain that is apparent from the observed line broadening and the reduction of the orientation tensor correlation coefficients. However, it is noted that only a few RDCs are detected in the kin-C, kinase C-lobe; kin-N, kinase N-lobe. *Domain definitions are provided in Table S2 .
† Correlation coefficients r between two tensors S N-lobe; as a consequence, structural precision is low. Furthermore, a structural ensemble would represent the expected mixture of N-lobe conformations better than a single structure, but the current paucity of data does not allow meaningful ensemble structure calculations.
Modeling by an ensemble of structures would also be more appropriate for the highly dynamic c-Abl•imatinib complex but was not attempted for the same reason. Fig. 4C depicts the bestscored single structure models for this complex. The SH2 and SH3 domains now adopt a wide range of different positions relative to the kinase N-and C-lobes, whereas the N-and C-lobes are fixed relative to each other in the same orientation as in the X-ray structure. Although this set of different conformations indicates that the calculations did not converge to a single structure, it is obvious that the kinase/SH3-SH2 interface is broken and the SH2-kinase linker is accessible.
Allosteric Transmission Routes of Ligand-Induced Structural Changes.
It is intriguing how imatinib binding to the ATP pocket achieves the observed dislocation of the remote SH3 and SH2 domains from the kinase. The available crystal structures of the isolated kinase domain in complex with imatinib [Protein Data Bank (PDB) ID code 1IEP; 2.1-Å resolution (39) ] and the closed form of the SH3-SH2/kinase in complex with PD166326 and myristic acid [PDB ID code 1OPK; 1.8-Å resolution (3)] provide no insight into this opening mechanism, because the isolated kinase domain•imatinib complex can be superimposed onto the full structure with only very minor variations in atom positions (<1 Å) at the kinase domain/SH3-SH2 interface.
In principle, chemical shift changes induced by the ligand binding could reveal finer changes of atom positions along the allosteric transmission route. For the case of a two-state equilibrium in fast exchange, covariance analysis of chemical shifts has been used to determine networks of coupled residues when binding a range of chemically similar ligands to one binding pocket (40) . A similar analysis for our case shows that a simple two-state model is not applicable, presumably because imatinib and GNF-5 bind to different locations. However, more conventional chemical shift maps for the various investigated forms of c-Abl provide some insights into the allosteric transmission routes. Fig. 5A shows averaged 1 H and 15 N chemical shift differences between the c-Abl•imatinib complex and apo c-Abl mapped onto the crystal structure of the closed state of c-Abl. A major part of the kinase around the ATP pocket, as well as larger parts of the SH3 and SH2 domains facing the kinase domain, exhibit strong chemical shift changes upon imatinib binding. However, no real conclusion on the signal transmission from the kinase to the SH3 and SH2 domains can be made, because it is expected that the opening of the entire structure results in large shift changes at the kinase/SH3-SH2 interface. More insight is obtained from a comparison of the c-Abl•imatinib/GNF-5 and c-Abl•GNF-5 complexes, because both are in the closed form. Surprisingly, strong chemical shift differences between these two forms ( 1/2 larger and smaller than 0.03 ppm are shown as red and blue spheres, respectively. In A, the threshold was raised to 0.07 ppm due to the large contribution of the opening of the entire structure to the chemical shift changes. Unassigned or overlapping residues are shown as a gray cartoon representation.
the SH3 domain at the interface to the kinase N-lobe and (to a lesser extent) in the upper part of the SH2 domain at the interface to the SH3 domain and the kinase C-lobe. These chemical shift changes give clear evidence that the structural change from the imatinib binding transmits from the kinase N-lobe directly to the SH3 domain and to the upper part of the SH2 domain.
In contrast, the chemical shift differences between the c-Abl•GNF-5 complex and apo c-Abl (both in the closed state; Fig. 5C ) are strictly limited to the immediate vicinity of the myristoyl-binding pocket. Thus, the structural effect of GNF-5 binding is much more localized.
Disruption of the SH3-SH2/Kinase Interface Exposes Y245 to Phosphorylation. The structural models for the c-Abl•GNF-5 and c-Abl•imatinib/GNF-5 complexes (Fig. 4 A and B) indicate that the SH3-SH2 domains are docked to the kinase domain and bury the SH2-kinase linker within the SH3-SH2/kinase interface. Based on the chemical shift and SAXS data, a very similar conformation must also be adopted by apo c-Abl. In this closed conformation, Y245 binds to the SH3 domain as part of an altered SH3-binding PXXP motif, where it replaces the second proline (41) . In contrast, the SH3-SH2 domains undock from the kinase domain and expose the SH2-kinase linker to the environment in the c-Abl•imatinib complex (Fig. 4C) . In consequence, Y245 may become susceptible to phosphorylation, which is expected to inhibit rebinding to the SH3 domain and keep c-Abl in an open conformation (41) . Indeed, its presence is necessary for full Abl activation, because a Y245F mutation reduces autophosphorylation-induced activation by 50% (42) .
To investigate the cellular consequences of these open and closed structures in the various forms of Abl further, we have carried out a phosphorylation ELISA to quantify total and Y245-specific tyrosine phosphorylation of Bcr-Abl from cell extracts. Ba/F3 cells expressing Bcr-Abl were incubated with serial dilutions of inhibitors, and phosphorylation was detected by either the generic anti-P-tyrosine antibody PY20 potentially recognizing all 14 possible phosphorylation sites or the antibody rb-antiAbl(Y245), which specifically recognizes the P-Y245 epitope. The obtained results, normalized to untreated Ba/F3 cells, are shown in Fig. 6 . As expected, the total tyrosine phosphorylation levels monotonically decrease with increasing concentration for the tested inhibitors GNF-5, imatinib, and nilotinib, with IC 50 values in the submicromolar range (Fig. 6, Left) . A very similar inhibition profile is observed for the specific phosphorylation of Y245 in the case of the allosteric inhibitor GNF-5 (Fig. 6, Right) . However, for the two ATP-binding site inhibitors imatinib and nilotinib, the specific inhibition profiles of Y245 phosphorylation are strikingly different. In both cases, Y245 phosphorylation initially increases upon inhibitor addition before decreasing. The increase is very significant, reaching maxima at 20 nM and 100 nM for nilotinib and imatinib, respectively. The concentration dependence of this effect for the two inhibitors follows a similar trend as the total inhibition of Abl tyrosine phosphorylation (IC50 nilotinib < IC50 imatinib ; Fig. 6 Discussion A large number of experimental data suggest that activation of Abl, sarcoma, and related kinases is achieved by the release of the SH3 and SH2 domains from their respective kinase domains (3, 5, 41) . In this open state, protein-protein interaction and phosphorylation sites become accessible for substrates as well as other kinases. In contrast, in the closed state, the SH3 and SH2 domains are in intimate contact with the kinase domain and kinase activity is suppressed.
We have shown here that apo c-Abl 83-534 is indeed closed, and hence presumably inactive. Hitherto, no structural information had been available on this state. It is interesting to note that in apo c-Abl 83-534 , only one of the three linchpins that were proposed to hold the closed state together (5) is present: There is only the docking of the SH3 domain to the polyproline helix in the SH2-kinase linker, but there is no myristoyl docking and no clamp by the N-terminal cap. Presumably, the latter two would stabilize the closed state even more. The importance of the SH3-linker interaction has been highlighted in a recent study, where an enhancement of this interaction by point mutations suppressed the kinase activity; reduced dynamics, as detected by hydrogen exchange mass spectrometry; and, surprisingly, sensitized BcrAbl to small-molecule inhibitors (43) .
In contrast to the apo state and rather counterintuitively, binding of imatinib to the ATP site opens c-Abl and releases the SH3 and SH2 domains from the kinase domain (Figs. 4 and 7) to form a dynamic open state. This observation may explain why no crystal structures have been obtained so far for imatinib-bound states of c-Abl comprising the SH2 and SH3 domains. Due to the blocking of the ATP site, the imatinib-induced open state, however, cannot have kinase activity. Thus, open and closed conformations of c-Abl need to be distinguished from the active and nonactive states of the kinase domain itself. We refer to this new state as an "open-inhibited" conformation.
In particular, the opening by imatinib makes Y245 located in the SH2-kinase linker accessible. This residue is necessary for full kinase activation (42) . Presumably Y245 phosphorylation disrupts binding to the SH3 domain and keeps the SH3-SH2/ kinase arrangement in an open conformation (3, 41) . The imatinib-induced open-inhibited state observed in vitro for c-Abl seems to be relevant in vivo also, because it can explain the unusual results on Y245 phosphorylation in full-length Bcr-Abl in Ba/F3 cells, where an increase in Y245 phosphorylation is observed in the presence of imatinib at concentrations near its IC 50 . If imatinib also opens the SH3-SH2/kinase domain arrangement in Bcr-Abl, Y245 becomes accessible for phosphorylation by other noninhibited Bcr-Abl molecules in its vicinity. In this context, it is interesting that Bcr-Abl forms dimers and tetramers through the aminoterminal coiled-coiled domain of Bcr (44, 45) . This oligomerization is an important activator of the kinase and transforming function of Bcr-Abl (44) . The proximity of Abl molecules within the oligomers should make trans-autophosphorylation highly effective such that the imatinib-induced opening of a fraction of monomers may lead to very efficient Y245 phosphorylation. This could serve as a priming mechanism for enhanced kinase activity (41) . Because a similar phosphorylation behavior is also observed for nilotinib, the Y245 phosphorylation assay may serve as an efficient method to detect opening of the Abl structure during drug screening, without additional structural data. Indeed, an opening of the kinase conformation by nilotinib, which is similar to imatinib, and also a similar GNF-5-induced closing of the ternary c-Abl•nilotinib/ GNF-5 complex became evident from a subsequent combined NMR and SAXS analysis of the respective c-Abl•nilotinib complexes (Fig. S5) .
The available chemical shift data provide insight into the transmission route by which imatinib binding dislocates the SH3 and SH2 domains from the kinase and opens the Abl structure. The forces seem to be predominantly transmitted from the kinase N-lobe to its neighboring SH3 domain (Fig. 5) , with possible involvement of the intervening SH2-kinase linker, for which no chemical shift assignments are available. A number of mutations in the interface between the SH3, SH2, and kinase itself have been described, which increase kinase activity presumably by opening the structure (46) (47) (48) . These mutants provide further evidence of direct interdomain interactions. In particular, this is the case for the salt bridge E117-K313 between the SH3 domain and the kinase N-lobe, where an E117K mutation, which breaks the salt bridge, is highly activating but the reciprocal E117K/ K313E mutation restores the inhibited form (46) . Strong chemical shift changes for residue E117 upon imatinib binding (Fig. 5  A and B) corroborate the involvement of this residue in the interdomain signaling. Salt bridges and also hydrogen bonds have very steep distance dependencies. Therefore, a slight rearrangement of the N-lobe, hardly detectable in the present crystallographic structures, may be sufficient to reduce the stabilizing energy to an extent that the open conformation of the kinase becomes dominant. For a sensitive regulation, the changes in the free energy difference between open and closed states should be rather minor; for example, a 10-fold change in the equilibrium constant, which would be compatible with the experimental NMR detection limit, would correspond to only 1.4 kcal/mol at body temperature. •imatinib complex recloses the structure (Figs. 4 and 7) . Therefore, binding of GNF-5 must stabilize the SH3-SH2/kinase domain interface. In the absence of myristoyl pocket ligands, the C-terminal helix αI of the isolated kinase is straight in crystals (3) and partially flexible in solution (21) (Fig. 7) . This straight helix αI, but also part of the flexible conformations, would clash with the SH2 domain in the closed SH3-SH2-kinase conformation (4). In contrast, binding of myristate (3, 4) and other ligands like GNF-2 (20, 21) and presumably GNF-5, induces a bent conformation resulting in a shorter helix αI and a kinked helix αI′ such that the clash is avoided. The dynamic behavior of helix αI′ in the absence of GNF-5 is evident in the NMR spectra from a broadening of resonances, whereas stabilization of the bent form by this allosteric inhibitor leads to observable resonances within helix αI′ (Fig. S6) . Presumably, this restriction to a single, nonclashing conformation provides the required free energy to close the open c-Abl 83-534 •imatinib complex. This mechanism will also add to the stabilization of the already closed apo state in the absence of an ATP site inhibitor. Because the closed state is in dynamic equilibrium with an occasionally open state, the inhibitory action of GNF-5 and analogs would then follow from a further shift toward the closed state. This is consistent with cellular and enzymatic assays that show GNF-5 inhibition of phosphorylation of Bcr-Abl and of an SH3-SH2-kinase domain construct but no inhibition of the isolated kinase domain (18, 19) . However, further studies are necessary to decipher experimentally additional details of this allosteric closing mechanism.
In summary, we have shown that open and closed conformations of c-Abl 83-534 under physiological solution conditions are in a delicate equilibrium, which can be shifted by the presence of inhibitors in both the ATP-binding and myristoyl-binding pockets. The required free energy changes for this shift could be as low as 1-2 kcal/mol, which would be expected for the necessary tight regulation of the cellular activity of Abl. It is hoped that the detailed understanding of this mechanism can help to explain the cellular response of Abl to inhibitors and to devise successful strategies to overcome drug resistance.
Methods
Protein Expression and Purification. The 83-534 fragment of c-Abl (Abl 1b numbering) containing an N-terminal His6-tag and a PreScission protease (GE Healthcare) site was coexpressed with protein tyrosine phosphatase 1b (residues 1-283) under the control of the T7 promotor in Escherichia coli strain BL21(DE3). The sequence of the expressed construct was therefore in the additional residues NMR Spectroscopy. Isotope-labeled proteins were typically concentrated to 150-200 μM in the presence of inhibitors or to ∼80 μM without inhibitors and exchanged against 20 mM Tris·HCl (pH 8.0), 100 mM NaCl, 2 mM EDTA, 2 mM TCEP, and 0.02% NaN 3 . All NMR experiments were performed at 303K on a Bruker AVANCE III 800-MHz spectrometer. Sequential assignment information was obtained from TROSY versions of the 3D HNCA, HNCO, and HNCACB (49), together with available assignments for the kinase domain (50) and the SH3-SH2 domains (51) . The 15 N relaxation rates (R 1 , R 2 ) were obtained from TROSY versions of standard 15 N relaxation experiments (52). The extent of assignment is summarized in Tables S1 and S2. All NMR data were processed with NMRPipe (53) and analyzed in SPARKY (54) .
Residual RDCs were obtained as differences in 1 H-15 N coupling constants detected by the ARTSY pulse sequence (55) under anisotropic and isotropic orientation. Anisotropic orientation was achieved by adding 15 mg/mL Pf1 bacteriophage (Asla Biotech) to the protein solutions. Mean and SDs for isotropic or anisotropic 1 H-15 N coupling constants were obtained from repeated measurements and statistical errors in RDC data derived by error propagation. Only RDC data with errors smaller than 5 Hz were retained for further analysis. Orientation tensors were fitted to the RDC data and the 1OPK crystal structure for each domain individually (Table S3 ) using a linear fit procedure (35) implemented in MATLAB (MathWorks).
SAXS. SAXS experiments were performed on the cSAXS-X12SA beamline at the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland). Because protein aggregation can obscure SAXS analysis, the data (q-range: 0.02-0.35 Å −1 ) were collected at three different concentrations (10, 5.0, and 2.5 mg/mL for c-Abl•imatinib and 6.0, 3.0, and 1.5 mg/mL for the other complexes) and extrapolated to zero concentration using the program PRIMUS (56) . Data of three independent measurements were averaged. For input to Xplor-NIH structure calculations, the q-range was restricted to <0.30 Å −1 and statistical experimental errors were estimated from the noise of the scattering curve. Radii of gyration, R gyr , and the maximum dimension of the scattering particle, D max , were obtained from an analysis of the particle distance distribution function with the program GNOM (57).
Molecular Modeling. Structure calculations were carried out in the program Xplor-NIH (version 2.28), using the structure of fully assembled c-Abl (PDB ID code 2FO0) as a starting point. The modeling followed a previous protocol to combine SAXS and RDC restraints (38) , and it consisted of (i) initial randomization of torsion angles within the linker regions with the SH3, SH2, and kinase N-and C-domains treated as rigid bodies; (ii) simulated annealing under the influence of experimental data in which the linkers are given Cartesian degrees of freedom; and (iii) conjoined rigid body/torsion angle/ Cartesian dynamics-simulated annealing refinement. During the final stage, domain backbones were treated as rigid bodies, whereas the side chains and linkers were given torsion angle and Cartesian degrees of freedom, respectively. For each complex, 200 structures were generated. Of these, a best set of 20 structures was selected by consecutive scoring for best agreement with RDCs (80 retained), best agreement with SAXS data (40 retained), and smallest total energy (38) .
Phosphorylation Assay. Ba/F3 cells engineered to express Bcr-Abl were seeded in 384-well plates at 100,000 cells per well and incubated for 1 h at 37°C with serial dilutions of compounds in a final volume of 50 μL (final DMSO concentration was 0.1%). Cell lysates were prepared by addition of 10 μL of lysis buffer (6× RIPA lysis buffer containing 12 mM sodium orthovanadate and the Complete Protease Inhibitor Mixture). Fifteen microliters of the lysates was then transferred to black 384-well Maxisorp ELISA plates (Thermo Fisher Scientific) that had been coated with a monoclonal anti-c-Abl capture antibody (A5844; Sigma) and blocked with 3% TopBlock (TB232010; Juro Supply). After 3 h of incubation at 4°C, plates were washed and 15 μL of secondary antibody (diluted in blocking buffer) per well was added. For detection of total tyrosine phosphorylation, a generic anti-P-tyrosine antibody labeled with alkaline phosphatase [PY-20(AP), 037722; Invitrogen] was used as the secondary antibody. For detection of specific Y245 phosphorylation, overnight incubation with the polyclonal rb-anti-Abl(Y245) antibody (2861; Cell Signaling Technology) was followed by 2 h of incubation with gtanti-rb IgG labeled with AP (A9919; Sigma). Captured AP activity was measured by the addition of 25 μL of the luminescent AP-substrate CDP-Star/ Emerald-II RTU (T2388C; Applied Biosystems) per well. After 1 h of incubation in the dark at room temperature, luminescence was quantified with a TopCount NXT Scintillation reader (Perkin Elmer). Untreated cells and cells treated with 1 μM BGG463 (58) were used as high and low controls, respectively.
